Chicagoland Peptides products are Research Use Only ("RUO") and are intended solely for basic research, pharmaceutical research, laboratory experimentation, or the development of new tests — not for diagnosing, treating, curing, or preventing any disease or condition in any patient. These statements have not been evaluated by the U.S. Food and Drug Administration.
Storage & Handling
Last reviewed: September 15, 2026
Peer-reviewed stability literature on lyophilised (solid) versus liquid (aqueous / reconstituted) peptide and protein samples, and on temperature, light, and freeze–thaw as experimental variables, is summarised below. Findings were reported in in vitro chemical and pharmaceutical studies, not as handling instructions for a named catalogue lot.
In a review of solid-state chemical stability of proteins and peptides, the authors stated that peptide and protein drugs are often formulated in the solid state to provide stabilization during storage, while chemical reactions including deamidation, peptide-bond cleavage, oxidation, the Maillard reaction, beta-elimination, and dimerization or aggregation can still occur in the solid state; temperature, moisture content, excipients, and amorphous versus crystalline physical state were listed as influencing factors.[1] In a review of protein stabilization in the solid state, the solid state was described as preferred for many proteins because of marginal stability in solution, while chemical and physical degradation were still reported to occur on the time scale of drying, distribution, and use.[2]
In a review of freeze-drying of bioproducts, product and process parameters that determine successful freeze-drying were related to thermochemical and thermomechanical properties of water-soluble amorphous materials.[3] In a review of liquid protein pharmaceuticals, protein instability was described as a reason protein pharmaceuticals are stored under cold conditions or freeze-dried to achieve an acceptable shelf life, and chemical and physical instability of proteins in liquid formulations was summarised.[4]
A 1989 review of protein-pharmaceutical stability summarised chemical pathways including proteolysis, deamidation, oxidation, racemization, and beta-elimination, and physical processes including aggregation, precipitation, denaturation, and adsorption to surfaces.[5]
In a review of photodegradation of protein biologics, residues reported to undergo primary photooxidation included tryptophan, tyrosine, phenylalanine, and cysteine or cystine, and photodegradation was described as able to change primary, secondary, and tertiary structure.[6]
In an in vitro study of proteins in aqueous solutions, freezing and thawing rates were reported to affect denaturation of the test proteins under the compared freeze–thaw conditions.[7]
In plain terms
Reviews of lab and pharmaceutical work said peptides and proteins are often kept as a solid — including lyophilised, meaning freeze-dried into a powder — because they tend to be less stable in liquid, though chemical and physical breakdown can still happen in the solid and during drying, shipping, and use.[1][2] Freeze-drying success was tied to how water-soluble amorphous materials (solids without a regular crystal lattice) behave with heat and moisture.[3] Reviews of liquid protein products likewise said cold storage or freeze-drying is used to reach an acceptable shelf life because proteins can be unstable in liquid form.[4]
A 1989 review summarised chemical breakdown paths such as chain cutting, deamidation (a chemical change to some amino acids), oxidation, and related reactions, plus physical changes such as clumping, falling out of solution, unfolding, and sticking to surfaces.[5] A review of light damage in protein biologics said certain amino acids can oxidise when lit, and that light damage can change primary, secondary, and tertiary structure (the chemical sequence and how the chain folds).[6]
In a lab study of proteins dissolved in water (in vitro), how fast samples were frozen and thawed was reported to affect denaturation, meaning unfolding or loss of the folded shape, of the test proteins under the compared freeze–thaw conditions.[7]
References
- Lai MC, Topp EM. Solid-state chemical stability of proteins and peptides.. Journal of pharmaceutical sciences. 1999. (in vitro) PubMed
- Chang LL, Pikal MJ. Mechanisms of protein stabilization in the solid state.. Journal of pharmaceutical sciences. 2009. (in vitro) PubMed
- Franks F. Freeze-drying of bioproducts: putting principles into practice.. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 1998. (in vitro) PubMed
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals.. International journal of pharmaceutics. 1999. (in vitro) PubMed
- Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals.. Pharmaceutical research. 1989. (in vitro) PubMed
- Kerwin BA, Remmele RL Jr. Protect from light: photodegradation and protein biologics.. Journal of pharmaceutical sciences. 2007. (in vitro) PubMed
- Cao E, Chen Y, Cui Z, Foster PR. Effect of freezing and thawing rates on denaturation of proteins in aqueous solutions.. Biotechnology and bioengineering. 2003. (in vitro) PubMed
